MHC-I-restricted HIV epitope processing, immune control and immunogen design

HIV Therapy

Volumn 4, Issue 1, 2010, Pages 101-117

  Le Gall, Sylvie ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antigen processing; CD8 T cells; HIV; Immune control; Immune escape; Peptidases; Prediction algorithm; Protective immune response; Protein degradation; Vaccine immunogen

Indexed keywords

CD8 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VACCINE;

CD8+ T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; REVIEW;

EID: 74849096983     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.09.57     Document Type: Review

References (212)

1. Barouch DH: Challenges in the development of an HIV-1 vaccine. Nature 455(7213), 613-619 (2008).
2. Buchbinder SP, Mehrotra DV, Duerr A et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
3. Mcelrath MJ, De Rosa SC, Moodie Z et al.: HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort ana lysis. Lancet 372(9653), 1894-1905 (2008).
4. Hanke T: Step trial and HIV-1 vaccines inducing T-cell responses. Expert Rev. Vaccines 7(3), 303-309 (2008).
5. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al.: Vaccination with ALVAC and AIDSvax to prevent HIV-1 infection in Thailand. N. Engl. J. Med. (2009). ■■ First HIV vaccine trial with some positive outcome.
6. Robb ML: Failure of the merck HIV vaccine: an uncertain step forward. Lancet 372(9653), 1857-1858 (2008).
7. Moore JP, Klasse PJ, Dolan MJ, Ahuja SK: AIDS/HIV. A step into darkness or light? Science 320(5877), 753-755 (2008). ■ Recent review on HIV vaccine.
8. Yang OO: Retracing our step towards a successful CTL-based HIV-1 vaccine. Vaccine 26(25), 3138-3141 (2008).
9. Pantaleo G: HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect. Dis. 8(2), 82-83 (2008).
10. Cohen J: HIV/AIDS research. Beyond Thailand: making sense of a qualified AIDS vaccine "success". Science 326(5953), 652-653 (2009).
11. Walker BD, Burton DR: Toward an AIDS vaccine. Science 320(5877), 760-764 (2008). ■ Recent review on HIV vaccine.
12. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189(6), 991-998 (1999).
13. + lymphocytes. Science 283(5403), 857-860 (1999).
14. + lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype. J. Virol. 79(23), 14887-14898 (2005).
15. Koup RA, Safrit JT, Cao Y et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68(7), 4650-4655 (1994).
16. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68(9), 6103-6110 (1994).
17. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3(11), 1061-1068 (2002).
18. Streeck H, Schweighardt B, Jessen H et al.: Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progression. AIDS 21(7), 889-891 (2007).
19. + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79(21), 13239-13249 (2005).
20. Allen TM, Altfeld M, Yu XG et al.: Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78(13), 7069-7078 (2004).
21. Borrow P, Lewicki H, Wei X et al.: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3, 205-211 (1997).
22. + cytotoxic T lymphocyte response. J. Exp. Med. 200(10), 1243-1256 (2004).
23. Brumme ZL, Brumme CJ, Heckerman D et al.: Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog. 3(7), e94 (2007). ■■ Large study on viral evolution according to HLA types.
24. Liu J, O'brien KL, Lynch DM et al.: Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457(7225), 87-91 (2009).
25. Reynolds MR, Weiler AM, Weisgrau KL et al.: Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J. Exp. Med. 205(11), 2537-2550 (2008).
26. Wilson CC, Newman MJ, Livingston BD et al.: Clinical Phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin. Vaccine Immunol. 15(6), 986-994 (2008).
27. Streeck H, Frahm N, Walker BD: The role of IFN-g ELISpot assay in HIV vaccine research. Nat. Protoc. 4(4), 461-469 (2009).
28. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75(24), 11983-11991 (2001).
29. + T cells in primary HIV-1 infection. J. Virol. 77(12), 6867-6878 (2003).
30. + responses in HIV type 1-infected patients: comparison with anti-Epstein-barr virus responses and changes during antiretroviral therapy. J. Virol. 73, 7108-7116 (1999).
31. Frahm N, Yusim K, Suscovich TJ et al.: Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur. J. Immunol. 37(9), 2419-2433 (2007).
32. Frahm N, Nickle DC, Linde CH et al.: Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. AIDS 22(4), 447-456 (2008).
33. Frahm N, Korber BT, Adams CM et al.: Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J. Virol. 78(5), 2187-2200 (2004).
34. Frahm N, Kaufmann DE, Yusim K et al.: Increased sequence diversity coverage improves detection of HIV-specific T cell responses. J. Immunol. 179(10), 6638-6650 (2007).
35. + T cell responses against HIV-1 are associated with delayed progression to AIDS. PLoS Med. 3(10), 1851-1863 (2006).
36. Altfeld M, Addo MM, Shankarappa R et al.: Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J. Virol. 77(13), 7330-7340 (2003).
37. + T cells. J. Virol. 83(15), 7641-7648 (2009).
38. Buseyne F, Mcchesney M, Porrot F, Kovarik S, Guy B, Riviere Y: Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24Gag protein. J. Virol. 67(2), 694-702 (1993).
39. Addo MM, Yu XG, Rathod A et al.: Comprehensive epitope ana lysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77(3), 2081-2092 (2003).
40. + T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J. Virol. 81(14), 7725-7731 (2007).
41. Altfeld M, Rosenberg ES, Shankarappa R et al.: Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193(2), 169-180 (2001).
42. Goulder PJ, Altfeld M, Rosenberg ES et al.: Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193(2), 181-194 (2001).
43. + T-cell responses following acute HIV-1 infection. J. Virol. 76(17), 8690-8701 (2002).
44. Altfeld M, Addo MM, Rosenberg ES et al.: Influence of HLA-b57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17(18), 2581-2591 (2003).
45. Draenert R, Verrill CL, Tang Y et al.: Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J. Virol. 78(2), 630-641 (2004).
46. + T-cell effector activity in HIV primary infection. J. Clin. Invest. 104(10), 1431-1439 (1999).
47. Day CL, Shea AK, Altfeld M et al.: Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J. Virol. 75(14), 6279-6291 (2001).
48. Dalod M, Harzic M, Pellegrin I et al.: Evolution of cytotoxic T lymphocytes responses to HIV-1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J. Infect. Dis. 178, 61-69 (1998).
49. Pereyra F, Addo MM, Kaufmann DE et al.: Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197(4), 563-571 (2008).
50. +-T-cell responses to the Gag protein of HIV-1 correlates inversely with viral load in plasma. J. Virol. 76, 2298-2305 (2002).
51. Frahm N, Kiepiela P, Adams S et al.: Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7(2), 173-178 (2006).
52. Frahm N, Goulder P, Brander C: Broad HIV-1 specific CTL responses reveal extensive HLA class I binding promiscuity of HIV-derived, optimally defined CTL epitopes. HIV Immunol. HIV/SIV Vaccine Databases 3-22 (2003).
53. Kiepiela P, Leslie AJ, Honeyborne I et al.: Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432(7018), 769-775 (2004). ■■ Importance of HLA B in immune pressure and viral evolution.
54. + T cells. PLoS Med. 5(5), e100 (2008).
55. + T cell epitope presented by closely related alleles from the HLA-A3 superfamily. Int. Immunol. 18(7), 1179-1188 (2006).
56. Horton H, Havenar-Daughton C, Lee D et al.: Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection. J. Virol. 80(19), 9779-9788 (2006).
57. + responses to viruses: cell biology, cellular immunology, and mathematical models. Immunity 21(2), 149-153 (2004).
58. Chen W, Anton LC, Bennink JR, Yewdell JW: Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12(1), 83-93 (2000). ■■ Important study on factors contributing to immunodominance.
59. Probst HC, Tschannen K, Gallimore A et al.: Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J. Immunol. 171(10), 5415-5422 (2003).
60. Van Baalen CA, Guillon C, Van Baalen M et al.: Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur. J. Immunol. 32(9), 2644-2652 (2002).
61. Buseyne F, Le Gall S, Boccaccio C et al.: MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med. 7(3), 344-349 (2001).
62. + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178(5), 2746-2754 (2007).
63. Le Gall S, Stamegna P, Walker BD: Portable flanking sequences modulate CTL epitope processing. J. Clin. Invest. 117(11), 3563-3575 (2007). ■■ First demonstration of impact of antigen processing on HIV immunodominance.
64. Lazaro E, Godfrey SB, Stamegna P et al.: Differential HIV epitope processing in monocytes and CD4 T cells affects cytotoxic T lymphocyte recognition. J. Infect. Dis. 200(2), 236-243 (2009).
65. Sette A, Vitiello A, Reherman B et al.: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153(12), 5586-5592 (1994).
66. Pion S, Christianson GJ, Fontaine P, Roopenian DC, Perreault C: Shaping the repertoire of cytotoxic T-lymphocyte responses: explanation for the immunodominance effect whereby cytotoxic T lymphocytes specific for immunodominant antigens prevent recognition of nondominant antigens. Blood 93(3), 952-962 (1999).
67. Trautmann L, Rimbert M, Echasserieau K et al.: Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus- specific CD8 T cell responses. J. Immunol. 175(9), 6123-6132 (2005).
68. Gonzalez PA, Carreno LJ, Coombs D et al.: T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc. Natl Acad. Sci. USA 102(13), 4824-4829 (2005).
69. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A: Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375(6527), 148-151 (1995). ■■ Pioneer study on MHC-I-epitope complex density and T-cell stimulation.
70. Weidanz JA, Nguyen T, Woodburn T et al.: Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J. Immunol. 177(8), 5088-5097 (2006).
71. Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN: Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J. Exp. Med. 180(4), 1283-1293 (1994).
72. Shacklett BL, Critchfield JW, Lemongello D: Quantifying HIV-1-specific CD8+ T-cell responses using ELISpot and cytokine flow cytometry. Methods Mol. Biol. 485, 359-374 (2009). ■ Detailed methodological on CD8 T-cell functions.
73. Mclaughlin BE, Baumgarth N, Bigos M et al.: Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: panel design by an empiric approach. Cytometry A 73(5), 400-410 (2008).
74. Wherry EJ, Ha Sj, Kaech SM et al.: Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27(4), 670-684 (2007). ■■ Mechanisms of T-cell exhaustion in chronic infection.
75. + T cell polyfunctionality, proliferation and cytotoxicity are not restored by antiretroviral therapy. J. Virol. (2009) (Epub ahead of print).
76. + T cells. Blood 107(12), 4781-4789 (2006). ■■ Important detailed study on HIV-specific cytotoxic T cells (CTL) functions in controllers.
77. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204(10), 2473-2485 (2007). ■■ Important detailed study on HIV-specific CTL functions in controllers.
78. Jin X, Wills M, Sissons JG, Carmichael A: Progressive loss of IL-2-expandable HIV-1-specific cytotoxic T lymphocytes during asymptomatic HIV infection. Eur. J. Immunol. 28(11), 3564-3576 (1998).
79. + T cells in GALT: implications for immune control of HIV-1 infection. J. Immunol. 173(1), 641-648 (2004).
80. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8(11), 1246-1254 (2007).
81. Day CL, Kaufmann DE, Kiepiela P et al.: Pd-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109), 350-354 (2006).
82. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10(1), 29-37 (2009).
83. Brumme ZL, Brumme CJ, Carlson J et al.: Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) GAG, POL, and NEF cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J. Virol. 82(18), 9216-9227 (2008).
84. Koibuchi T, Allen TM, Lichterfeld M et al.: Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection. J. Virol. 79(13), 8171-8181 (2005).
85. Ferre AL, Hunt PW, Critchfield JW et al.: Mucosal immune responses to HIV-1 in elite controllers: A potential correlate of immune control. Blood 113(17), 3978-3989 (2009).
86. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29(6), 1009-1021 (2008). ■■ Important detailed study on HIV-specific CTL functions in controllers.
87. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH: Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203(10), 2223-2227 (2006). ■■ Important study on reversion of immune-cell exhaustion.
88. Kaufmann DE, Walker BD: PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J. Immunol. 182(10), 5891-5897 (2009).
89. Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD: Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc. Natl Acad. Sci. USA 94(21), 11478-11483 (1997).
90. Chen H, Piechocka-Trocha A, Miura T et al.: Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J. Virol. 83(7), 3138-3149 (2009). ■■ Important detailed study on HIV-specific CTL antiviral functions.
91. + T cells is unrelated to epitope specificity and is abrogated by viral escape. J. Virol. 81(6), 2624-2634 (2007).
92. + cell responses. J. Infect. Dis. 192(9), 1588-1596 (2005).
93. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13(1), 46-53 (2007). ■■ Link between viral load and protein specificity of CTL.
94. Zuniga R, Lucchetti A, Galvan P et al.: Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J. Virol. 80(6), 3122-3125 (2006).
95. Rolland M, Heckerman D, Deng W et al.: Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 3(1), e1424 (2008).
96. Loureiro J, Ploegh HL: Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Adv. Immunol. 92, 225-305 (2006).
97. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM: Endocytosis of MHC-I molecules is induced by HIV-1 Nef. Nat. Med. 2, 338-342 (1996).
98. Le Gall S, Erdtmann L, Benichou S et al.: Nef interacts with m subunits of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC-I molecules. Immunity 8, 483-495 (1998).
99. Allen TM, Altfeld M: Crippling HIV one mutation at a time. J. Exp. Med. 205(5), 1003-1007 (2008).
100. Moore CA, John M, James R, Christiansen FT, Witt CS, Mallal SA: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296(5572), 1439-1443 (2002).
101. Brumme ZL, Tao I, Szeto S et al.: Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. AIDS 22(11), 1277-1286 (2008).
102. Goulder PJ, Philipps RE, Colbert RA et al.: Late escape from an immunodominant cytotoxic T-lymphocyte associated with progression to AIDS. Nat. Med. 3, 212-217 (1997).
103. Feeney ME, Tang Y, Roosevelt KA et al.: Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-b27-positive long-term-nonprogressing child. J. Virol. 78(16), 8927-8930 (2004).
104. Allen TM, Yu XG, Kalife ET et al.: De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J. Virol. 79(20), 12952-12960 (2005).
105. Feeney ME, Tang Y, Pfafferott K et al.: HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J. Immunol. 174(12), 7524-7530 (2005).
106. Brockman MA, Schneidewind A, Lahaie M et al.: Escape and compensation from early HLA-b57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J. Virol. 81(22), 12608-12618 (2007).
107. Goepfert PA, Lumm W, Farmer P et al.: Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J. Exp. Med. 205(5), 1009-1017 (2008). ■■ Viral evolution and fitness in transmission pair studies.
108. Schneidewind A, Brockman MA, Yang R et al.: Escape from the dominant HLA-b27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 81(22), 12382-12393 (2007).
109. Altfeld M, Allen TM: Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol. 27(11), 504-510 (2006). ■■ Interesting review on HIV viral evolution.
110. Deeks SG, Walker BD: Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27(3), 406-416 (2007).
111. + long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral Gag sequences. J. Virol. 77(12), 6889-6898 (2003).
112. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L: Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin. Infect. Dis. 40(9), 1350-1354 (2005).
113. Lambotte O, Boufassa F, Madec Y et al.: HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41(7), 1053-1056 (2005).
114. Klein MR, Van Der Burg GH, Hovenkamp E et al.: Characterization of HLA-b57-restricted human immunodeficiency virus type 1 Gag-and RT-specific cytotoxic T lymphocyte responses. J. Gen. Virol. 79, 2191-2201 (1998).
115. Hubert JB, Burgard M, Dussaix E et al.: Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The seroco study group. AIDS 14(2), 123-131 (2000).
116. Goulder PJ, Tang Y, Pelton SI, Walker BD: HLA-b57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other. J. Virol. 74(11), 5291-5299 (2000).
117. Lambotte O, Deiva K, Tardieu M: HIV-1 persistence, viral reservoir, and the central nervous system in the haart era. Brain Pathol. 13(1), 95-103 (2003).
118. Saez-Cirion A, Pancino G, Sinet M, Venet A, Lambotte O: HIV controllers: how do they tame the virus? Trends Immunol. 28(12), 532-540 (2007). ■ Interesting review on HIV controllers.
119. + T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J. Virol. 83(4), 1845-1855 (2009).
120. Schneidewind A, Brockman MA, Sidney J et al.: Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-b27-restricted epitope in human immunodeficiency virus type 1 capsid. J. Virol. 82(11), 5594-5605 (2008).
121. Miura T, Brockman MA, Schneidewind A et al.: HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare Gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. J. Virol. 83(6), 2743-2755 (2009). ■■ Extensive study on viral replicative capacity in controllers.
122. Miura T, Brockman MA, Brumme ZL et al.: HLA-associated alterations in replication capacity of chimeric nl4-3 viruses carrying Gag-protease from elite controllers of human immunodeficiency virus type 1. J. Virol. 83(1), 140-149 (2009).
123. Miura T, Brockman MA, Brumme CJ et al.: Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J. Virol. 82(17), 8422-8430 (2008).
124. Saez-Cirion A, Lacabaratz C, Lambotte O et al.: HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl Acad. Sci. USA 104(16), 6776-6781 (2007).
125. Shacklett BL, Critchfield JW, Ferre AL, Hayes TL: Mucosal T-cell responses to HIV: responding at the front lines. J. Intern. Med. 265(1), 58-66 (2009).
126. Altshuler D, Daly MJ, Lander ES: Genetic mapping in human disease. Science 322(5903), 881-888 (2008).
127. Catano G, Kulkarni H, He W et al.: HIV-1 disease-influencing effects associated with znrd1, hcp5 and HLA-c alleles are attributable mainly to either HLA-a10 or HLA-b*57 alleles. PLoS One 3(11), e3636 (2008).
128. Fellay J, Shianna KV, Ge D et al.: A whole-genome association study of major determinants for host control of HIV-1. Science 317(5840), 944-947 (2007).
129. Siddiqui RA, Sauermann U, Altmuller J et al.: X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. Am J. Hum. Genet. 85(2), 228-239 (2009).
130. Limou S, Le Clerc S, Coulonges C et al.: Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS genomewide association study 02). J. Infect. Dis. 199(3), 419-426 (2009).
131. Trachtenberg E, Bhattacharya T, Ladner M, Phair J, Erlich H, Wolinsky S: The HLA-b/-c haplotype block contains major determinants for host control of HIV. Genes Immun. (2009) (Epub ahead of print).
132. Brass AL, Dykxhoorn DM, Benita Y et al.: Identification of host proteins required for HIV infection through a functional genomic screen. Science 319(5865), 921-926 (2008).
133. Kloetzel PM: Generation of major histocompatibility complex class I antigens: Functional interplay between proteasomes and TPPII. Nat. Immunol. 5(7), 661-669 (2004).
134. Goldberg AL: On prions, proteasomes, and mad cows. N. Engl. J. Med. 357(11), 1150-1152 (2007).
135. Goldberg A, Cascio P, Saric T, Rock KL: The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39(3-4), 147-164 (2002).
136. Kisselev A, Akopian T, Woo KM, Goldberg AL: The sizes of peptides generated from protein by mammalian 26 and 20S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J. Biol. Chem. 274(6), 3363-3371 (1999).
137. Cascio P, Hilton C, Kisselev AF, Rock KL, Goldberg A: 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 20(10), 2357-2366 (2001).
138. Craiu A, Akopian T, Goldberg A, Rock KL: Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc. Natl Acad. Sci. USA 94(20), 10850-10855 (1997).
139. Khan S, Van Den Broek M, Schwarz K, De Giuli R, Diener PA, Groettrup M: Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J. Immunol. 167(12), 6859-6868 (2001).
140. Griffin TA, Nandi D, Cruz M et al.: Immunoproteasome assembly: cooperative incorporation of interferon γ (IFN-γ)-inducible subunits. J. Exp. Med. 187(1), 97-104 (1998).
141. Gaczynska M, Goldberg A, Tanaka K, Hendil KB, Rock KL: Proteasome subunits x and y alter peptidase activities in opposite ways to the interferon-γ-induced subunits LMP2 and LMP7. J. Biol. Chem. 271(17275-17280), (1996).
142. Macagno A, Kuehn L, De Giuli R, Groettrup M: The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. Eur. J. Immunol. 31(11), 3271-3280 (2001).
143. Morel S, Levy F, Burlet-Schiltz O et al.: Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12(1), 107-117 (2000).
144. Schultz ES, Chapiro J, Lurquin C et al.: The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-b40 requires the immunoproteasome. J. Exp. Med. 195(4), 391-399 (2002).
145. Sewell AK, Price DA, Teisserenc H et al.: IFN-γ exposes a cryptic cytotoxic T lymphocytes epitope in HIV-1 reverse transcriptase. J. Immunol. 162, 7075-7079 (1999).
146. Kuckelkorn U, Ferreira EA, Drung I, Liewer U, Kloetzel PM, Theobald M: The effect of the interferon-γ-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context. Eur. J. Immunol. 32(5), 1368-1375 (2002).
147. Macagno A, Kuehn L, De Giuli R, Groettrup M: Pronounced up-regulation of the PA28A/B proteasome regulator subunit but little increase in the steady-state content of immunoproteasome during dendritic cell maturation. Eur. J. Immunol. 31, 3271-3280 (2001).
148. Saric T, Beninga J, Graef CI, Akopian T, Rock KL, Goldberg AL: Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J. Biol. Chem. 276(39), 36474-36481 (2001).
149. Beninga J, Rock KL, Goldberg A: Interferon-γ can stimulate post-proteasomal trimming of the n terminus of an antigenic peptide by inducing leucine aminopeptidase. J. Biol. Chem. 273(30), 18734-18742 (1998).
150. York IA, Mo Axy, Lemerise K et al.: The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 18(3), 429-440 (2003). ■■ Important study on peptide degradation in the cytosol.
151. Serwold T, Shastri N: Specific proteolytic cleavages limit the diversity of the pool of peptides available to MHC class I molecules in living cells. J. Immunol. 162(8), 4712-4719 (1999).
152. Geier E, Pfeifer G, Wilm M et al.: A giant protease with potential to substitute for some functions of the proteasome. Science 283(5404), 978-981 (1999).
153. Reits E, Neijssen J, Herberts C et al.: A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20(4), 495-506 (2004).
154. Seifer U, Maranon C, Shmueli A et al.: An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 4(4), 375-379 (2003).
155. York IA, Bhutani N, Zendzian S, Goldberg AL, Rock KL: Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J. Immunol. 177(3), 1434-1443 (2006).
156. Wherry EJ, Golovina TN, Morrison SE et al.: Re-evaluating the generation of a "proteasome-independent" MHC class I-restricted CD8 T cell epitope. J. Immunol. 176(4), 2249-2261 (2006).
157. Lauvau G, Kakimi K, Niederman G et al.: Human transporters associated with antigen processing (TAP) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells. J. Exp. Med. 190(9), 1227-1240 (1999). ■■ Important study on transporter associated with antigen processing substrate specificity.
158. Gubler B, Daniel S, Armandola EA, Hammer J, Caillat-Zucman S, Van Endert PM: Substrate selection by transporters associated with antigen processing occurs during peptide binding to tap. Mol. Immunol. 35(8), 427-433 (1998).
159. Neefjes J, Gottfried E, Roelse J et al.: Analysis of the fine specificity of rat, mouse and human tap peptide transporters. Eur. J. Immunol. 25(4), 1133-1136 (1995).
160. Neisig A, Roelse J, Sijts AJ et al.: Major differences in transporter associated with antigen presentation (tap)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J. Immunol. 154(3), 1273-1279 (1995).
161. Abele R, Tampe R: Function of the transport complex tap in cellular immune recognition. Biochim. Biophys. Acta 1461(2405-2419), (1999).
162. Saric T, Chang SC, Hattori A et al.: An IFN-γ-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 3(12), 1169-1176 (2002). ■■ Discovery of a novel aminopeptidase involved in endoplasmic reticulum (ER) epitope processing.
163. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N: ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419(3), 480-483 (2002). ■■ Discovery of a novel aminopeptidase involved in ER epitope processing.
164. York IA, Chang SC, Saric T et al.: The ER aminopeptidase ERAPI enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat. Immunol. 3(12), 1177-1184 (2002). ■■ Discovery of a novel aminopeptidase involved in ER epitope processing.
165. Saveanu L, Carroll O, Lindo V et al.: Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat. Immunol. 6(7), 689-697 (2005). ■■ Important study on mechanisms of ER epitope processing.
166. Koopmann JO, Albring J, Huter E et al.: Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the sec61p channel. Immunity 13(1), 1127-1137 (2000).
167. Fonteneau JF, Kavanagh DG, Lirvall M et al.: Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood 102(13), 4448-4455 (2003).
168. + T lymphocytes. Proc. Natl Acad. Sci. USA 101(16), 6092-6097 (2004).
169. Larsson M, Fonteneau JF, Lirvall M, Haslett P, Lifson JD, Bhardwaj N: Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. AIDS 16(10), 1319-1329 (2002).
170. Saveanu L, Carroll O, Weimershaus M et al.: IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science 325(5937), 213-217 (2009). ■■ Identification of a novel aminopeptidase involved in epitope cross-presentation.
171. Moris A, Nobile C, Buseyne F, Porrot F, Abastado JP, Schwartz O: DC-SIGN promotes exogenous MHC-i-restricted HIV-1 antigen presentation. Blood 103(7), 2648-2654 (2004).
172. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S: ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425(6956), 397-402 (2003). ■■ Dissection of mechanisms of peptide cross-presentation.
173. Shen L, Rock KL: Cellular protein is the source of cross-priming antigen in vivo. Proc. Natl Acad. Sci. USA 101(9), 3035-3040 (2004).
174. Ackerman AL, Kyritsis C, Tampe R, Cresswell P: Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat. Immunol. 6(1), 107-113 (2005).
175. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA: Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol. Rev. 207, 145-157 (2005). ■ Review on antigen processing and cross-presentation.
176. + T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J. Immunol. 175(7), 4618-4626 (2005).
177. Lucchiari-Hartz M, Van Endert PM, Lauvau G et al.: Cytotoxic T lymphocyte epitopes of HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J. Exp. Med. 191(2), 239-252 (2000).
178. Lucchiari-Hartz M, Lindo V, Hitziger N et al.: Differential proteasomal processing of hydrophobic and hydrophilic protein regions: Contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef. Proc. Natl Acad. Sci. USA 100(13), 7755-7760 (2003).
179. Levy F, Burri L, Morel S et al.: The final N-terminal trimming of a subaminoterminal proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two peptidases. J. Immunol. 169(8), 4161-4171 (2002).
180. + T cell epitopes: wealth of HLA-binding motifs and sensitivity to proteasome degradation. J. Immunol. 166(10), 6164-6169 (2001).
181. Samino Y, Lopez D, Guil S, Saveanu L, Van Endert PM, Del Val M: A long N-terminal-extended nested set of abundant and antigenic major histocompatibility complex class I natural ligands from HIV envelope protein. J. Biol. Chem. 281(10), 6358-6365 (2006).
182. Draenert R, Le Gall S, Pfafferott KJ et al.: Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J. Exp. Med. 199(7), 905-915 (2004). ■■ First identification of antigen processing mutation leading to immune escape in HIV infection.
183. Kisselev AF, Garcia-Calvo M, Overkleeft HS et al.: The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J. Biol. Chem. 278(38), 35869-35877 (2003).
184. Kisselev AF, Kaganovich D, Goldberg AL: Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20S proteasomes. Evidence for peptide-induced channel opening in the α-rings. J. Biol. Chem. 277(25), 22260-22270 (2002).
185. Kisselev AF, Callard A, Goldberg AL: Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem. 281(13), 8582-8590 (2006).
186. Kisselev AF, Akopian TN, Castillo V, Goldberg AL: Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol. Cell 4(3), 395-402 (1999).
187. Saric T, Graef CI, Goldberg AL: Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J. Biol. Chem. 279(45), 46723-46732 (2004).
188. York IA, Brehm MA, Zendzian S, Towne CF, Rock KL: Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc. Natl Acad. Sci. USA 103(24), 9202-9207 (2006).
189. Chang SC, Momburg F, Bhutani N, Goldberg AL: The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc. Natl Acad. Sci. USA 102(47), 17107-17112 (2005).
190. Evnouchidou I, Momburg F, Papakyriakou A et al.: The internal sequence of the peptide-substrate determines its N-terminus trimming by ERAP1. PLoS One 3(11), e3658 (2008).
191. Tenzer S, Wee E, Burgevin A et al.: Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat. Immunol. 10(6), 636-646 (2009). ■■ Important study on HIV antigen processing and immunodominance.
192. Couillin I, Culmann-Penciolelli B, Gomard E et al.: Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 Nef protein. J. Exp. Med. 180(3), 1129-1134 (1994).
193. Bergmann CC, Tong L, Cua R, Sensitaffar J, Stohlman S: Differential effects of flanking residues on presentation of epitopes from chimeric peptides. J. Virol. 68(8), 5306-5310 (1994).
194. Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Kosinowski UH: Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66(6), 1145-1153 (1991).
195. Yellen-Shaw AJ, Eisenlohr LC: Regulation of class I-restricted epitope processing by local or distal flanking sequence. J. Immunol. 158(4), 1727-1733 (1997).
196. Gileadi U, Gallimore A, Van Der Bruggen P, Cerundolo V: Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. Eur. J. Immunol. 29(7), 2213-2222 (1999).
197. Shastri N, Serwold T, Gonzalez F: Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. J. Immunol. 155(9), 4339-4346 (1995).
198. Mo AX, Van Lelyveld SF, Craiu A, Rock KL: Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides. J. Immunol. 164(8), 4003-4010 (2000).
199. Theobald M, Ruppert T, Kuckelkorn U et al.: The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med. 188(6), 1017-1028 (1998).
200. Beekman NJ, Van Veelen PA, Van Hall T et al.: Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J. Immunol. 164(4), 1898-1905 (2000).
201. Kimura Y, Gushima T, Rawale S, Kaumaya P, Walker CM: Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis c virus infection. J. Virol. 79(8), 4870-4876 (2005).
202. Seifert U, Liermann H, Racanelli V et al.: Hepatitis C virus mutation affects proteasomal epitope processing. J. Clin. Invest. 114(2), 250-259 (2004).
203. Rolland M, Nickle DC, Mullins JI: HIV-1 group M conserved elements vaccine. PLoS Pathog. 3(11), e157 (2007).
204. Nickle DC, Rolland M, Jensen MA et al.: Coping with viral diversity in HIV vaccine design. PLoS Comput. Biol. 3(4), e75 (2007).
205. Thurmond J, Yoon H, Kuiken C et al.: Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 24(14), 1639-1640 (2008).
206. Fischer W, Perkins S, Theiler J et al.: Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13(1), 100-106 (2007).
207. Kesmir C, Van Noort V, De Boer RJ, Hogeweg P: Bioinformatic ana lysis of functional differences between the immunoproteasome and the constitutive proteasome. Immunogenetics 55(7), 437-449 (2003).
208. Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H: Paproc: a prediction algorithm for proteasomal cleavages available on the www. Immunogenetics 53(2), 87-94 (2001).
209. Hakenberg J, Nussbaum AK, Schild H et al.: Mappp: MHC class I antigenic peptide processing prediction. Appl. Bioinformatics 2(3), 155-158 (2003).
210. Tenzer S, Peters B, Bulik S et al.: Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, tap transport and MHC class I binding. Cell. Mol. Life Sci. 62(9), 1025-1037 (2005).
211. Nussbaum AK, Kuttler C, Tenzer S, Schild H: Using the world wide web for predicting CTL epitopes. Curr. Opin. Immunol. 15(1), 69-74 (2003).
212. Schatz MM, Peters B, Akkad N et al.: Characterizing the N-terminal processing motif of MHC class I ligands. J. Immunol. 180(5), 3210-3217 (2008).